Mycofenolate mofetil

Phase 2Small molecule

EEastern Cooperative Oncology Group

Mycofenolate mofetil is one of 23 small molecule programs targeting Transplantation. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TransplantationCompleted

TransplantationPhase 2

Completed

Competition

Competitive Landscape

28 competitors in Transplantation

#DrugCompanyPhaseTrials

Atgam

Novartis

Phase 3

5 2

Rituxan

Roche

Phase 3

5 3

Prograf

VVeloxis Pharmaceuticals

Phase 3

12 4

Olumiant

Eli Lilly

Phase 3

1 5

Fludara

Sanofi

Phase 2

14 6

Neupogen

EEastern Cooperative Oncology Group

Phase 3

3 7

Cytoxan

BBaxter Healthcare Corporation

Phase 2

14 8

Trexall

Jazz Pharmaceuticals

Phase 2

3 9

Alkeran

Keppra

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Transplantation

NCT06828796

Clinical

Trials by Indication[1]

Transplantation2 trials

Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01010217·176 enrolled

Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide

Recruiting·NNorthside Hospital, Inc.·Phase 2·NCT06828796·20 enrolled

De Novo Renal Transplantation1 trial

Prospective Donor Specific T Response Measurment for IS Minimization in de Novo Renal Transplantation

Completed·PProf. Dr. Petra Reinke·N/A·NCT02540395·184 enrolled

Efficacy and Safety1 trial

A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . .

Terminated·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT00451867·210 enrolled

Myelodysplastic Syndromes1 trial

Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00045305·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Mycofenolate mofetil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mycofenolate mofetil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mycofenolate mofetil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eastern Cooperative Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEastern Cooperative Oncology Group

Mycofenolate mofetil

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Transplantation2 trials

De Novo Renal Transplantation1 trial

Efficacy and Safety1 trial

Myelodysplastic Syndromes1 trial

References

Drug Info

Quick Facts

Related News